Clinical Trial Update: FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating FX06 to rescue acute respiratory distress syndrome in COVID-19 pneumonia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia
• Respiratory Distress Syndrome

Drugs mentioned

• FX06

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Ards, Covid19 | Phase 2 | Status: COMPLETED